Peregrine Pharmaceuticals, Inc. (PPHM) Misses Q2 Loss Views; Revs Stronger
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q2 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $2.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Newell Rubbermaid (NWL) Tops Q4 EPS by 1c; Trims FY15 Outlook
- Eli Lilly & Co. (LLY) Tops Q4 EPS by 1c; Trims FY15 Revs Outlook
- Beazer Homes (BZH) Posts Q1 Loss of 68c/Share
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!